Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated at StockNews.com
Analysts at StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) in a note issued to investors on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock. A number of other brokerages have also commented on CYCC. Roth Mkm raised their price objective on shares of Cyclacel Pharmaceuticals […]
More Stories
US Government Plans to Borrow More This Quarter Amid Disappointing Tax Receipts
By Andrew Moran The U.S. government plans to borrow more cash from private investors this quarter than initially forecast amid...
Dershowitz Says Bragg’s Case Against Trump Will Fail Because It’s Based on Fake Crimes
By Tom Ozimek Retired Harvard law professor Alan Dershowitz said on April 28 that he believes that Manhattan District Attorney...
Heart Failure Mortality Rates Surge to Highest Levels in 20 Years
By Megan Redshaw, J.D. An unprecedented number of people are dying from heart failure, completely reversing long-standing declines in cardiovascular...
Security Council hears of progress in Bosnia despite ‘worrying’ trend of genocide denial
Both positive and “worrying” developments have recently unfolded in Bosnia and Herzegovina, a top UN official told the Security Council...
Guterres calls on Israel and Hamas to end Gaza war
With the situation in Gaza “worsening by the day”, UN Secretary-General António Guterres on Tuesday appealed for Israeli and Hamas...
Will There Be a Snowfall Season 7? Here’s What Creators Said
More than a year after Snowfall Season 6 premiered, there are developments regarding the anticipation for Snowfall Season 7. As...